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Cyr61 has been reported to participate in the development and progression of various cancers; however, its role in prostate cancer
(PCa) still remains poorly understood. In this study, we explored the function of Cyr61 in a series of malignant PCa cell lines, including
LnCap, Du145, and PC3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and crystal violet assays demonstrated
that Cyr61 was essential for the proliferation of PCa cells. Soft agar assay and xenograft analysis showed that downregulation of Cyr61
suppressed the tumorigenicity of Du145 cells both in vitro and in vivo. Either silencing the cellular Cyr61 by RNA interference or
neutralising the endogenous Cyr61 by antibody inhibited the migration of Du145 cells. In contrast, purified protein of Cyr61
promoted the migration of LnCap cells in a dose-dependent manner. These results suggested that Cyr61 was involved in the
migration of PCa cells. We also observed the accumulation of mature focal adhesion complexes associated with the impaired
migration through Cyr61 downregulation. Also, further studies showed that Cyr61 regulated the level of activated Rac1 as well as its
downstream targets, including phosphorylated JNK, E-cadherin, and p27
kip1, which are key molecules involved in cell growth,
migration, and invasion. The in vivo mouse tail vein injection experiment revealed that Cyr61 affected the metastatic capacity of Du145
cells, suggesting that Cyr61 was required for prostate tumour metastasis. Altogether, our results demonstrated that Cyr61 played an
important role in the tumorigenicity and metastasis of PCa cells, which will benefit the development of therapeutic strategy for PCas.
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Prostate cancer (PCa) is one of the main diseases influencing men
today, ranked the third most common cancer worldwide (Ziober
et al, 2001; Sim and Cheng, 2005). Though the molecular
mechanisms underlying remain poorly understood, accumulating
evidence indicates the involvement of various growth factors in the
development and progression of PCa (Ware, 1998; Melton et al,
2007), such as insulin-like growth factor (Gennigens et al, 2006),
vascular endothelial growth factor (Delongchamps et al, 2006),
transforming growth factor-b (Zhu and Kyprianou, 2005),
epidermal growth factor (Spiegel and Milstien, 2005), and
hepatocyte growth factor (Hurle et al, 2005).
CCN growth factor family is named after the three first identified
members – Cyr61 (cysteine-rich protein 61, CCN1), CTGF
(connective tissue growth factor, CCN2), and Nov (nephroblastoma
overexpressed, CCN3) (Bork, 1993). So far, this family has included
six members: Cyr61, CTGF, Nov, WISP-1 (Wnt-1-induced secreted
protein 1) (CCN4), WISP-2 (CCN5), and WISP-3 (CCN6) (Brigstock,
2003; Perbal, 2004). All CCN molecules share four conserved
structural modules with sequence homologies similar to cysteine
knot, thrombospondin, von Willebrand factor, and insulin-like
growth factor-binding protein, respectively (Bork, 1993). Earlier
studies have reported that CTGF and Nov promoted tumorigenesis
of PCa (Maillard et al, 2001; Yang et al, 2005), whereas the
expression of Cyr61 was downregulated in PCa (Pilarsky et al, 1998).
Cyr61 was the first cloned member of the CCN family and
reported to mediate a variety of cellular processes, including cell
adhesion, stimulation of chemostasis, enhancement of growth
factor-induced DNA synthesis, cell survival, and angiogenesis
(Grzeszkiewicz et al, 2002; Lin et al, 2004). Moreover, Cyr61 has
been reported to be involved in the development of several kinds
of tumours (Bleau et al, 2005). Overexpressed Cyr61 could
stimulate the progression of breast cancers (Xie et al, 2001a,b).
A gastric adenocarcinoma cell line became more tumorigenic when
the cells were genetically engineered to express high levels of Cyr61
(Babic et al, 1998). High expression level of Cyr61 was reported in
rhabdomyosarcomas, malignant melanomas, colon adenocarcino-
mas, and bladder papillomas (Genini et al, 1996; Babic et al, 1998).
Cyr61 also exhibited high levels in malignant gliomas and
enhanced the tumorigenicity through the integrin-linked kinase
signalling pathway (Xie et al, 2004). Upregulation of Cyr61
expression was recently identified in peritoneal metastases from
human pancreatic cancer (Holloway et al, 2005). Paradoxically,
Cyr61 was downregulated in lung cancers, and forced expression
of Cyr61 inhibits tumorigenicity of lung cancer cells (Tong et al,
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s2001, 2004). Cyr61 was also reported to inhibit the growth of
endometrial cancer (Chien et al, 2004) and leiomyomas (Sampath
et al, 2001).
Although it has been reported that Cyr61 was upregulated and
required for prostatic cell proliferation in benign prostatic
hyperplasia (Sakamoto et al, 2004), there are rare reports on the
role of Cyr61 in malignant PCa cells. In this study, therefore, we
investigated the functions of Cyr61 in Du145, a high-grade
metastatic PCa cell line (Stone et al, 1978), and found that Cyr61
played an essential role in the proliferation, migration, and
metastasis of this PCa cells both in vitro and in vivo.
MATERIALS AND METHODS
Prostate cancer tissue samples and cell lines
Twenty pairs of primary PCa samples and their corresponding
normal tissues were obtained from PCa patients treated at the First
Affiliated Hospital of Zhengzhou University (Henan, China) from
2002 to 2005 after their written informed consent, and none of the
patients received any neoadjuvant therapy. All specimens were
frozen at once in liquid nitrogen after surgical excision and stored
at  801C until use. Our study was approved by the Institutional
Review Board of the Institute for Nutritional Sciences, Chinese
Academy of Sciences. PC3, Du145, LnCap, and 22RV1 cells were
purchased from the American Type Culture Collection (Manassas,
VA, USA) and cultured in RPMI-1640, supplemented with 10%
foetal bovine serum, 10Uml
 1 penicillin, and 10Uml
 1 strepto-
mycin, at 371C in a humidified atmosphere containing 5% CO2.
Reagents
Rabbit anti-human Cyr61 polyclonal antibody was purchased from
Santa Cruz Biotechnology (SC-13100(H-78); Santa Cruz, CA, USA);
anti-focal adhesion kinase (anti-FAK, clone 77), anti-Rac1 (clone
102), anti-paxillin (clone 68), FAK (pY397), Paxillin (pY118), anti-
phosphorylated JNK (pT183/pY185, clone 41), and pan-p-JNK
(clone 37) monoclonal antibodies were from BD Transduction
Laboratories (San Diego, CA, USA); Rac1-specific inhibitor
NSC23766 was purchased from EMD Biosciences (Darmstadt,
Germany); Lipofectamine 2000 was from Invitrogen (Carlsbad,
CA, USA); 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was from Roche Molecular Biochemicals (Basel,
Switzerland); and D-luciferin was from Biosynth International
Inc.(Naperville, IL, USA).
RNA interference of Cyr61 and rescue experiments
To knock down the endogenous Cyr61, we selected three siRNA
hairpin sequences against different sites of Cyr61 mRNA that were
designed using Ambin web software: (1) GGCCAGAAATGTA
TTGTTC; (2) GAAATGCAGCAAGACCAAG; and (3) GAACGTCA
TGATGATCCAG. These sequences were cloned to the FG12 vector
and RNA interference (RNAi) cell lines were produced as
described previously (Qin et al, 2003). A silent mutant Cyr61
expression construct was made resistant to an siRNA sequence.
Between the nucleic acids 676 and 694, GGCCAGAAATGTATTG
TTC were replaced with GGACAAAAGTGCATCGTAC. The silent
mutant Cyr61 was delivered into the Cyr61-silenced Du145 cells
with lentivirus (Figure 1H).
Forced expression of Cyr61 in Du145 and LnCap cells
A modified lentivirus-based FG12 vector with a CMV promoter to
introduce Cyr61 gene was expressed in Du145 and LnCap cells
(Qin et al, 2003). After infection, the cells were sorted by FACS to
collect GFP-positive cells.
Western blot analysis
Total cell lysates (40mg of protein) were separated by 10% SDS–
PAGE gels and electrotransferred onto polyvinylidene difluoride
membranes (Millipore, Bedford, MA, USA). After blocking with
5% milk, the membranes were probed with primary antibodies at
1:1000 dilutions. The membrane was washed and then incubated
with horseradish peroxidase-conjugated secondary antibodies
for 1h. Immunoreactive proteins were detected with enhanced
chemiluminescence reagents (Pierce, Rockford, IL, USA) and
photographed with Kodak X-Omat blue autoradiography film.
Cell proliferation analysis
To analyse the effect of Cyr61 on PCa cell proliferation activity,
MTT assay and crystal violet assay were taken. In MTT assay, cells
were plated into 96-well plates at 2 10
3 cells per well, cultured in
0.5B1% FBS RPMI-1640 for various durations, and cell numbers
were measured by MTT assay according to the protocol provided
by MTT manufacturer. In crystal violet assay, equal number of
cells and their control cells were seeded in 12-well plates and
cultured in media supplemented with 0.5B1% FBS for 7 days;
media were changed every other day. Cellular growth was stopped
after 7 days in culture by removing the media and adding 0.5%
crystal violet solution in 20% methanol. After staining for 5min,
the fixed cells were washed with phosphate-buffered saline (PBS)
and photographed (Thomas et al, 2004).
Soft agar assay
Cells were plated in 24-well flat-bottomed plates using a two-layer
soft agar system with 1 10
3 cells per well in a volume of 400ml per
well as described earlier (Munker et al, 1986). After 14 days of
incubation, colonies were counted and measured. All the experi-
ments were repeated at least three times using triplicate plates per
experimental point.
Purification of recombinant hCyr61 protein
Cyr61 was cloned into PIZT/V5-His vector between EcoRI and
XbaI, followed by transfecting into SF9 insect cells with Cellfectin
(Invitrogen). Cells were selected for antibiotic resistance to Zeocin.
A Zeocin-resistant pool of cells stably expressed secreted r-hCyr61
recombinant protein. Cyr61-contained medium was collected and
the recombinant protein was purified with chromatography on
Ni
2þ metal-chelating resins.
Tumorigenesis assay in vivo
Stably infected and FACS-sorted cells (1 10
7 cells per flank)
suspended in 200ml of RPMI and 150ml Matrigel were injected into
5-week-old female SCID mice (CB-17TM/IcrCrl-scidBR) purchased
from Shanghai Laboratory Animal Center, CAS (Shanghai, China)
and treated in accordance with the American Association for the
Accreditation of Laboratory Animal Care guidelines. Each animal
was subcutaneously injected at two sites in the flanks. The
resulting tumours were measured once a week and tumour volume
(mm
3) was calculated using the standard formula: length 
width height 0.5236. Tumours were harvested 8 weeks after
injection and individually weighed.
Wound-healing assays
Cells were seeded onto six-well dishes at 1 10
5 per well in growth
medium. Confluent monolayers were starved overnight in assay
medium and a single scratch wound was created using a
micropipette tip. Cells were washed with PBS to remove cell
debris, supplemented with assay medium, and monitored. Images
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swere captured by phase microscopy using a  10 objective at 0 and
24h post-wounding. The percentage of cells in the wound-healing
area was averagely calculated from four experiments.
Boyden chamber assay
Boyden chamber (8-mm pore size polycarbonate membrane) was
obtained from Neuroprobe Corp., Bethesda, MD, USA. Cells
(2 10
5) in 0.05ml medium with 1% FBS were placed in the upper
chamber, and the lower chamber was loaded with 0.152ml medium
containing 10% FBS. Cells that migrated to the lower surface of
filters were detected with traditional H&E staining, and five fields
of each well were counted after 4–24h of incubation at 371C with
5% CO2. Three wells were examined for each condition and cell
type, and the experiments were repeated thrice. For inhibitor
experiment, the migrated cells were detected as described above
only after overnight incubation with or without series concentra-
tions of NSC23766.
Cloning and production of GST-PAK-CD fusion protein
The Rac1 activity assay was based on the Rap1 activity assay
described by Franke et al (1997). We used a glutathione-
S-transferase (GST)-PAK-CD (PAK-CRIB domain) fusion protein,
containing the Rac1- and Cdc42-binding regions from human
PAK1B (GenBank accession number AF071884). A fragment
encoding amino acids 56–272 of PAK1B was generated by
standard PCR using the oligos 50-AGCTGGATCCATTTTACCTG
GAGAT-30 and 50-AGCTCTCGAGATTTCTGGCTGTTGGATGTC-30,
digested with BamHI/XhoI, and then inserted between BamHI with
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Figure 1 Silencing of Cyr61 inhibited the proliferation of Du145 cells. (A) The protein level of Cyr61 in four PCa cell lines. (B) Du145 cells were infected
with lentivirus either expressing Cyr61 siRNA (Du145/Cyr61i) or the control siRNA (Du145/Ctrli), which processed the same A/T composition but
different sequences, and not matched with any genes. Three sequences of either Cyr61 siRNA or control siRNA were designed. Lane a: Du145/Ctrli #1
cells; lane b: Du145/Cyr61i #1 cells; lane c: Du145/Ctrli #2 cells; lane d: Du145/Cyr61i #2 cells; lane e: Du145/Ctrli #3 cells; lane f: Du145/Cyr61i #3 cells;
and lane g: wild-type Du145 (Du145/WT) cells. Tubulin was the loading control of protein samples. (C) In vitro proliferation of Du145/WT, Du145/Ctrli #1,
Du145/Cyr61i #1, and Du145/Cyr61i-Cyr61SM cells was examined by MTT assay. (D) Crystal violet assay of colony formation of Du145/Cyr61i #1 and
Du145/Ctrli #1 cells. Cells (3 10
3) were seeded each well in 12-well plates and photographed 2 weeks later. Number of cells was measured by detecting
under OD 600nm. A typical experiment was shown. (E) Crystal violet assay of PC3/Ctrl, PC3/Cyr61i, PC3/Cyr61i-Cyr61SM and PC3/Cyr61 cells was taken
under the same way. (F) Du145 cells were infected with lentivirus expressing both EGFP and control RNAi or Cyr61 RNAi as evidenced by representative
light-field or fluorescence photos. (G) LnCap cells were infected with lentivirus either expressing Cyr61 (LnCap/Cyr61) or the control GFP (LnCap/GFP).
In vitro proliferation of LnCap/Cyr61 and LnCap/GFP cells was examined by MTT assay. (H) Schematic diagram showing the domain structure of wild-type
Cyr61, silent mutation of Cyr61. Six nucleic acid changed Cyr61SM without changing the amino acid of Cyr61 making it resistant to the RNA interference
function of 1# siRNA sequence. *Po0.05, **Po0.01, Student’s t-test.
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sXhoI sites of pGEX4T1 (Pharmacia Biotech, Piscataway, NJ, USA)
to yield GST-PAK-CD. Escherichia coli BL21 cells transformed with
the GST-PAK-CD construct were grown at 371C to an absorbance
of 0.3. Expression of recombinant protein was induced by the
addition of 0.1mM isopropylthiogalactoside for 2h. Cells were
harvested, resuspended in lysis buffer (50mM Tris pH 8, 2mM
MgCl2, 0.2mM Na2S2O, 10% glycerol, 20% sucrose, 2mM dithio-
threitol, 1mgml
 1 leupeptin, 1mgml
 1 pepstatin, and 1mgml
 1
aprotinin), and then sonicated. Cell lysates were centrifuged at 41C
for 20min at 45000g and the supernatant was incubated with
glutathione-coupled Sepharose 4B beads (Pharmacia Biotech) for
30min at 41C. Protein bound to the beads was washed three times
in lysis buffer and the amount of bound fusion protein was
estimated using Coomassie-stained SDS gels.
Rac1-GTP pull-down assay
The Rac1 activity assay was performed by pull-down using GST
fusion with the protein-binding domain of p21-activated kinase
(GST-CIRB). Briefly, Du145 cells were plated onto the plate at a
density of approximately 2 10
6 cells per 10cm dish. When grown
to 60–70% confluence, cells were washed twice with PBS, then
lysed for 5min in 250ml ice-cold eukaryotic lysis buffer (25mM
Tris (pH 7.4) 1mM EDTA, 5mM MgCl2,1m M DTT, 0.1mM EGTA,
100mM NaCl, 1% NP-40, 5% glycerol, 1mM PMSF, 1mgml
 1
aprotinin, 1mgml
 1 leupeptin and 1mgml
 1 pestatin) and then
incubated for 30min with GST-PAK fusion protein that had been
adsorbed to glutathione agarose beads. Beads were washed three
times with 500ml of cold eukaryotic lysis buffer and then
resuspended in 10ml reducing electrophoresis sample buffer (2%
SDS, 10% glycerol, 80mM (Tris pH 6.8), 2mM EDTA, 100mM DTT,
and 0.1% bromophenol blue) and analysed by SDS–PAGE in a
12% gel. Following electrophoresis, samples were transferred to a
nitrocellulose membrane and immunoblotted with mouse anti-
human Rac1 antibody at a dilution of 1:1000. Normalised Rac1
activity values were determined by dividing the amount of Rac1 in
the pull-down by the amount of Rac1 in the loading control.
In vivo bioluminescence imaging of tumour cells
Du145 cells were transfected with plasmids expressing firefly
luciferase (PGL4-CMV-Luc2; Longmed Corporation, Beijing,
China) using Lipofectamine 2000. Cells were selected for antibiotic
resistance with G418. The surviving colonies were screened for
bioluminescence in complete media supplemented with
150mgml
 1 D-luciferin by in vitro imaging using the IVIS_
Imaging System (Xenogen, Alameda, CA, USA). Bioluminescent
antibiotic-resistant clones were amplified in culture and char-
acterised for stable luminescence in vitro and tumorigenic
potential in vivo. One positive cell line, Du145-luc2-7, was selected
for further studies. Du145-luc2-7 cells were infected with control
siRNA virus (Du145-Luc2/Ctrli), Cyr61 siRNA virus (Du145-Luc2/
Cyr61i), null virus (Du145-Luc2/GFP), and Cyr61 expression virus
(Du145-Luc2/Cyr61), respectively. Four pools of Du145-Luc2/Ctrli,
Du145-Luc2/Cyr61i, Du145-Luc2/GFP, and Du145-Luc2/Cyr61
were acquired after FACS sorting. They were injected, respectively,
into the nude mice from the tail vein. Mice were anaesthetised by
inhalation of 3% isoflurane/oxygen mixture delivered by the
Xenogen XGI-85-port gas anaesthesia system. Imaging and image
analysis were performed following the Xenogen protocol using a
cooled CCD camera system (IVIS-100; Xenogen) and LivingImage
software (Xenogen). The photographs were taken weekly.
Immunohistochemistry
For immunohistochemistry, primary PCa samples and their
corresponding normal tissues were frozen in a cryostat chamber,
and 10mm sections were collected on glass slides. The sections
were fixed in ice-cold acetone for 30min, washed in 0.01 M PBS
(8mM Na2HPO4,2m M NaH2PO4, and 150mM NaCl) for 3 5min,
blocked for 1h in 0.01 M PBS supplemented with 0.3% Triton
X-100 and 5% normal goat serum, and then incubated with Cyr61
antibody (1:500) at 41C overnight. After brief washes in 0.01 M
PBS, sections were incubated for 2h in 0.01 M PBS with horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:1000), followed by
development with 0.003% H2O2 and 0.03% DAB in 0.05 M Tris-HCl
(pH 7.6). Immunohistochemistry for each sample was performed
at least three times, and all sections were counterstained with
haematoxylin.
Statistical analysis
The results were representative of at least three independent
experiments performed in triplicate and were expressed as the
mean±s.d. Statistical analysis of the data was performed using
Student’s t-test.
RESULTS
Cyr61 stimulated the growth of PCa cells in vitro
We first examined the expression of Cyr61 in the four PCa cell
lines 22RV1, LnCap, Du145, and PC3. In Figure 1A, the two highly
malignant cell lines – PC3 and Du145 – exhibited significantly
higher Cyr61 expression, whereas Cyr61 was nearly undetectable in
the other two less malignant cell lines – LnCap and 22RV1
(Figure 1A). The level of Cyr61 in Du145 cells was fairly moderate
among the four PCa cell lines; therefore, we explored the function
of Cyr61 in Du145 cells by siRNA and antibody neutralisation, as
well as forced expression and protein treatment, whereas over-
expression and r-hCyr61 protein stimulation were employed in the
study on LnCap cells.
After successful knockdown of endogeneous Cyr61 by RNAi
(Figure 1B), we examined the cell growth using MTT assay, and the
result showed that downregulation of Cyr61 in DU145 cells
resulted in an obvious decrease in proliferation. Consistent with
this, the introduction of the silent mutant Cyr61 rescued Cyr61
expression and the proliferation of Du145 cells (Figure 1C and H).
Crystal violet experiment showed that the clones derived from
Du145/Cyr61i cells were much smaller and fewer than those
formed by Du145/Ctrli cells; in contrast, elevated Cyr61 level
stimulated Du145 cells to form larger and more clones (Figure 1D).
Similar results could also be observed in PC3 cells (Figure 1E).
These results suggested that downregulation of Cyr61 Du145 cell
proliferation and forced expression of Cyr61 in LnCap cells
promoted cell proliferation (Figure 1G). Therefore, Cyr61 was
required for the proliferation of PCa cells, which were consistent
with their function reported in benign prostatic hyperplasia
(Sakamoto et al, 2004).
Cyr61 promoted the tumorigenicity of Du145 cells both
in vitro and in vivo
As the knockdown of Cyr61 inhibited the proliferation of PCa cells,
we wondered whether it would affect the tumorigenicity either.
Soft agar test was carried out to examine the anchorage-
independent growth, which is a typical characteristic of the
tumorigenicity of cancer cells in vitro (Dodson et al, 1981; Grisham
et al, 1991). Du145/Ctrli, Du145/Cyr61i, Du145/Cyr61i-Cyr61SM,
and Du145/Cyr61 cells were inoculated on the upper layer of soft
agar. After 2 weeks, a number of obvious colonies of Du145/Ctrli
cells were observed in each well, whereas much fewer colonies were
formed by Du145/Cyr61i cells. Rescuing Cyr61 expression in
Du145/Cyr61i cells by byCyr61SM resulted in almost as many
colonies as those formed by Du145/Ctrli cells. Furthermore, the
colonies derived from Du145/Cyr61i-Cyr61SM cells were larger
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sthan those from Du145/Cyr61i cells. Forced expression of Cyr61 in
Du145 cells produced more and larger colonies when compared
with the Du145/Ctrli cells (Figure 2A). These results indicated that
Cyr61 promoted the tumorigenicity of Du145 cells in vitro.
To further examine the effect of Cyr61 on the tumorigenicity of
Du145 cells in vivo, either Du145/Cyr61i or Du145/Ctrli cells were
subcutaneously injected into nude mice. Tumour volumes were
measured every 7 days, and the result showed that Du145/Cyr61i
cells formed much smaller tumours when compared with Du145/
Ctrli cells (Figure 2C). Four weeks later, the mice were killed and
all the tumours were weighed. In accordance with their volumes,
the weight of tumours from Du145/Cyr61i cells was lighter than
those derived from Du145/Ctrli cells (Figure 2D). Proteins from the
xenografts were extracted and the expression of Cyr61 was
examined. As shown in Figure 2B, the level of Cyr61 in the
Du145/Cyr61i xenografts was lower than that in the Du145/Ctrli
xenografts. These data thus suggested that Cyr61 downregulation
also impaired the tumorigenicity of Du145 cells in vivo.
Cyr61 was essential for the migration of PCa cells in vitro
A number of studies have identified that Cyr61 functioned as a
ligand of integrins (Kireeva et al, 1998) that play pivotal roles in
cell migration (Hood and Cheresh, 2002; Carragher and Frame,
2004; Juliano et al, 2004; Moschos et al, 2007). Thus, we
investigated the effects of Cyr61 on the mobility of Du145 and
LnCap cells, which bore different levels of Cyr61 expression,
respectively. Wound-healing results demonstrated that much fewer
Du145/Cyr61i cells moved into the wound area than the Du145/
Ctrli cells in the same interval (Figure 3A). Similarly, Boyden
chamber assay revealed that the migration ability was impaired in
Du145/Cyr61i cells compared with Du145/Ctrli cells (Figure 3B).
To further confirm the effect of Cyr61 on cell migration, we used
antibodies against Cyr61 (SC-13100) to block the endogenous
Cyr61 in Du145 cells. Consistent with the results of an earlier
study, the Boyden chamber assay showed that the migration was
markedly suppressed upon antibody blocking (Figure 3C). As
Cyr61 is a secreted protein, we hypothesised that Cyr61 exerted its
effect on migration in a paracrine manner. To examine this
hypothesis, we purified r-hCyr61 protein from insect cells and
treated the LnCap cells, which express very low levels of Cyr61,
with the r-hCyr61 protein. Expectedly, LinCap cells showed
elevated migration ability in a dosage-dependent manner in
r-hCyr61 protein treatment (Figure 3D). Thus, these results
suggested that Cyr61 was closely involved in the migration of
PCa cells.
Downregulation of Cyr61 increased focal adhesion
assembly in Du145 cells
As the effects of integrins on migration often involve the regulation
of focal adhesion (FA) (Miyamoto et al, 1995; Burridge and
Chrzanowska-Wodnicka, 1996), we examined the status of FA after
downregulation of Cyr61 by immunofluorescence of FAK (Figure
4A and B) and paxillin (Figure 4C and D), both of which serve as
markers of FA (Miyamoto et al, 1995; Burridge and Chrzanowska-
Wodnicka, 1996). As shown in Figure 4E, Du145/Cyr61i cells
formed more FAs than Du145/Ctrli cells. Box-and-whisker plots of
paxillin-positive-stained points within Du145/Ctrli or Du145/
Cyr61i plated on FN for 8h are shown. In Du145/Ctrli cells, the
staining of FAK (Figure 4A) and paxillin (Figure 4C) was weak
and mainly appeared on the polarised edge. In contrast, in
Du145/Cyr61i cells, the staining signals of (Figure 4B) both FAK
and paxillin (Figure 4D) were much more intense and exhi-
bited uniform membrane distribution. This difference indicated
altered FA assembly (Miyamoto et al, 1995; Burridge and
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Figure 2 Silencing of Cyr61 suppressed the tumorigenicity of Du145 cells. (A) Soft agar assay showed that Du145/Cyr61i #1 cells formed much fewer
colonies in comparison with Du145/Ctrli #1 cells. Rescued expression of Cyr61 with cyr61 silent mutation and forced expression of cyr61 with lentivirus
form much more and larger compared with the Cyr61/Cyr61i. (B) Xenografts were taken out after the mice were killed. Cyr61 expression level was
detected by western blot. (C) Du145/Cyr61i #1 or Du145/Ctrli #1 cells (1 10
7) were subcutaneously injected into the dorsal skin of nude mice. Tumour
volumes were measured every 7 days, and each point represented the mean volume±s.d. from five independent experiments. (D) Four weeks later, the
mice were killed and the tumours were picked up for weighing. Each histogram represented the mean weight±s.d. from five independent experiments.
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sChrzanowska-Wodnicka, 1996). Phosphorylated FAK or paxillin,
which are activated forms of the molecule, was probed with anti-
FAK (pY397) or anti-paxillin (pY118) monoclonal antibodies,
respectively. The phosphorylation level of both FAK and paxillin
was elevated upon silencing of Cyr61 (Figure 3F), which indicated
the increased activation of the two molecules. As the increase of
FA often promotes the adhesion of host cells with the extracellular
matrix and the loss of polar distribution of FA inhibits cell
mobility (Hood and Cheresh, 2002; Carragher and Frame, 2004),
the alteration of FA assembly in Du145/Cyr61i cells was consistent
with their impaired mobility.
Effect of Cyr61 on PCa cell migration was mediated
through the activity of Rac1
To address the molecular mechanisms by which Cyr61 regulated
the migration of Du145 cells, we further examined some key
molecules involved in the integrin signalling pathways, such as
ERK, AKT, and JNK (Juliano et al, 2004). In Du145/Cyr61i and the
Du145/Ctrli cells, the activating forms of both ERK and AKT were
almost the same (data not shown), whereas the activated JNK
markedly decreased in the Du145/Cyr61i cells (Figure 5E).
Previous studies have proved that the small GTP-binding protein
Rac1 played a key role in the phosphorylation of JNK as well as cell
migration (Juliano et al, 2004). Therefore, we assumed that the loss
of activated JNK might be induced by a decreased level of activated
Rac1. To test our hypothesis, the activated Rac1 was pulled down
with GST-PKA (see Materials and Methods), and the result showed
that there was much less activated Rac1 in Du145/Cyr61i cells
than in Du145/Ctrli cells (Figure 5A). For further studying the
molecular mechanism, we compared the activation of Rac1 in
LnCap and Du145 cells overexpressing Cyr61 (LnCap/Cyr61 and
Du145/Cyr61) with that in their parental cells. As expected,
Cyr61 overexpression indeed enhanced the activation of Rac1
(Figure 5A) as well as the migration in both LnCap and Du145 cells
(Figure 5B and C). To confirm that the influence of Cyr61 on the
migration of PCa cell was Rac1 dependent, we employed a specific
inhibitor NSC23766 for Rac1 to manipulate the activity of
endogeneous Rac1 in LnCap/Cyr61 and Du145/Cyr61 cells. As
shown in Figure 5B and C, the migration could be inhibited by
NSC23766 in both LnCap and Du145 cells (Figure 5B and C). To
further confirm the effect of Rac1 on Cyr61-induced cell migration,
we transfected the Du145/Cyr61i cells with T-cell lymphoma
invasion and metastasis 1 (Tiam1), which was reported as a
specific activator of Rac1 (Hamelers et al, 2005; Cruz-Monserrate
and O’Connor, 2008). Tiam1-transfected Du145/Cyr61i cells
effectively reversed the migration-suppression effects of Cyr61
silencing (Figure 5D).
Besides JNK, we also looked into other molecules downstream of
Rac1, which are involved in both cell proliferation and migration.
Protein level of E-cadherin was elevated in Cyr61-silenced Du145
and PC3 cells. p27
kips, a famous CDK suppressor that was recently
reported to have an important suppression function in cell
migration (Bremnes et al, 2002; Supriatno et al, 2003), was also
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Figure 3 Silencing of Cyr61 inhibited the migration of Du145 cells. (A) Wound-healing assay for either Du145/Ctrli #1 or Du145/Cyr61i #1 cells.
(B) Boyden chamber assay for Du145/Ctrli #1 or Du145/Cyr61i #1 cells, and the cells migrated through the polycarbonate membrane were counted
following H&E staining. Student’s t-test (*Po0.01). (C) Boyden chamber assay for Du145 cells treated with either rabbit IgG (Fc) or the antibody against
Cyr61 (anti-Cyr61) and the cells migrated through the polycarbonate membrane were counted following H&E staining. Student’s t-test (*Po0.01).
(D) Boyden chamber assay for LnCap cells treated with either BSA (1mgml
 1) or the purified Cyr61-his protein. Cyr61 stimulates LnCap cell migration in a
dosage-dependent manner.
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supregulated during silencing of Cyr61 in Du145 cells (Figure 5E).
Therefore, the effects of Cyr61 on migration of Du145 cells might
be mainly mediated through Rac1 signalling.
Cyr61 stimulates Du145 metastasis in vivo and Cyr61
expression profile in clinical samples
Considering the effect of Cyr61 on cell migration, we suspect it
might also influence the metastasis of PCa cells in vivo. First, we
constructed Du145-Luc2 cells, which were stably transfected with a
firefly luciferase gene (see Materials and Methods), and subse-
quently infected with lentivirus delivering Cyr61 siRNA (Du145-
Luc2/Cyr61i), control siRNA (Du145-Luc2/Ctrli), null (GFP only),
or Cyr61, respectively. Four pools enriched with Du145-Luc2/
Cyr61i, Du145-Luc2/Ctrli, Du145-Luc2/GFP, and Du145-Luc2/
Cyr61 cells were selected by FACS. Also, cells from each pool
were injected into the mouse through tail vein. It is well known
that an important procedure of tumour metastasis in vivo is the
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Figure 4 Silencing of Cyr61 changed the intensity and distribution of focal adhesion. Immunofluorescence of FAK and paxillin, two markers of focal
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Figure 5 Rac1 was implicated in the regulation of Du145 cell migration by Cyr61. (A) Protein levels of Cyr61 following forced expression of Cyr61 in
Du145 cells. Lane a: Du145/WT cells; lane b: Du145 cells infected with lentivirus expressing GFP (Du145/GPF); lane c: Du145 cells infected with Cyr61
expression lentivirus (Du145/Cyr61). Activity of Rac1 was detected following silencing (down left) or forced expression of Cyr61 in Du145 cells (up right)
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sformation of new colonies of tumour cells after movement in blood
vascular system (Steeg, 2006), and the experimental model we used
mimicked this process. As shown in Figure 6A, Du145-Luc2/Ctrli
cells formed more tumour foci, which could be detected by
bioluminescence imaging after a relatively short latency; whereas
Du145-Luc/Cyr61i cells produced no tumour foci in the same
time period. The average metastasis lesions were quantitated
(Figure 6C). To exclude the possibility that the signal examined
might be artificial, after the mouse were killed, we found out the
metastasis lesions according to the previously obtained data
(Figure 6D). Student’s t-test revealed statistically significant
difference between the control and Cyr61-silenced groups
(Po0.01). Similarly, the Du145-Luc2/Cyr61 cells led to much
more metastasis lesions than Du145-Luc2/GFP cells (Figure 6B).
Conclusively, the results indicated the crucial role of Cyr61 in the
metastasis of Du145 cells in vivo.
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Figure 6 Silencing of Cyr61 eliminated the systemic tumour growth of Du145 cells in vivo.( A, B, C, and D) Either Du145-Luc2/Ctrli #1 or Du145-Luc2/
Cyr61i #1 cells (1 10
7) and 5 10
6 of either Du145-Luc2/GFP or Du145-Luc2/Cyr61 cells were injected into each 10 mice tail vein separately. The
bioluminescence images were acquired using the IVIS imaging box at indicated time points. Representative mice (8# and 10#) of Du145-Luc2/Ctrli #1,
Du145-Luc2/Cyr61i #1 (A) and Du145-Luc2/GFP, Du145-Luc2/Cyr61 (B) were presented for each time point. (C) Average number of metastasis lesions
was qualified. (D) The metastasis lesion was picked out to confirm that bioluminescence signalling is not artificial. (E) Immunohistochemistry of Cyr61 in
clinical prostate cancer samples and matched normal prostate tissue. Scale bar¼100mm. (F) Elevation of Cyr61 level upon tissue adjacent to tumour and
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sCyr61 expression was changed with PCa progression
After analysing the Cyr61 expression profile in the gene expression
array-based database of human metastatic prostate tumours and
primary prostate tumours (GSE6919), we found that the normal
prostate tissues showed very low level of Cyr61 expression,
whereas the tumour-adjacent tissues and the tumour tissues
demonstrated a significantly higher expression level of Cyr61
(Po0.001, Figure 6F). However, the expression level of Cyr61 in
metastatic prostate tumour samples decreased when compared
with that in the early stage of PCa (Figure 6F).
Metastasis largely results from the interaction between tumour
cells and the surrounding environment. Yang et al (2005) found
that mesenchymal stem cells within tumour stroma promoted
breast cancer metastasis through the secretion of the chemokine
CCL5. It was reported that the stromal expression of IGFBP3 was
important for PCa progression (Massoner et al, 2008). Recently,
Karnoub et al (2007) reported that stromal expression of CTGF
promoted angiogenesis and tumorigenesis of PCa. These findings
indicated the potential function of stromal Cyr61 in metastasis and
tumour progression. Consistent with these studies, we found that
Cyr61 indeed existed in the fibroblast cells in the region of
cancerous tissues (Figure 6E). We further analysed the expression
of Cyr61 in 20 pairs of clinical malignant PCa samples and their
matched normal prostate tissues by immunostaining. A represen-
tative result showed that the expression of Cyr61 was mild in both
epithelial cells and stromal fibroblast cells in normal prostate
tissues, whereas higher level of Cyr61 expression was observed in
epithelial PCa foci and the stromal fibroblast cells in tumour
samples (Figure 6E), which indicated that Cyr61 played a
promotive role in the tumorigenesis of PCa and served as an
important paracrine growth factor to prompt the metastasis of
malignant PCa cells.
DISCUSSION
In this study, we explored the functions of Cyr61 in several
representative PCa cell lines, including LnCap, Du145, and PC3
cells, and found that Cyr61 facilitated the proliferation and
migration of the tumour cells, suggesting that Cyr61 might act as
an oncoprotein in PCas.
Cyr61 is a well-established ligand for several integrins (Kireeva
et al, 1998), including avb3 and a6b1, which were expressed in
Du145 cells (Witkowski et al, 1993). Responding to the alteration
of extracellular environment, for example, in ligand engagement,
integrins can elicit intracellular signal pathways to regulate cell
survival, proliferation, gene transcription, adhesion to ECM, and
migration (Hood and Cheresh, 2002; Carragher and Frame, 2004;
Juliano et al, 2004; Moschos et al, 2007). Earlier studies have
demonstrated that Cyr61 induced cell proliferation, adhesion, and
angiogenesis through activation of integrin (a ´va ˆ3) in endothelial
cells (Babic et al, 1998). It was possible that the effect of Cyr61
exerted in Du145 cells might also be mediated through integrins.
In fact, we observed that the loss of Cyr61 facilitated the
assembly of FAs, which is the intermediate for the interaction
between cytoskeleton and ECM, and is largely regulated by integrin
signalling pathways (Miyamoto et al, 1995; Burridge and
Chrzanowska-Wodnicka, 1996; Juliano et al, 2004). Integrin-
induced assembly or disassembly of FAs often resulted in the
enhancement or attenuation of cell adhesion to the ECM,
respectively, and the dynamic regulation of FA was a crucial
determinant in cell migration (Hood and Cheresh, 2002; Carragher
and Frame, 2004). The recruitment of many factors including FAK
and paxillin promoted the assembly of FA, thus stabilising the
interaction between cytoskeleton and ECM, which enhanced the
cell adhesion while inhibited cell migration (Hood and Cheresh,
2002; Carragher and Frame, 2004). In contrast, the degradation or
separation of FA components led to the disassembly of FA and
elevated cell motility (Hood and Cheresh, 2002; Carragher and
Frame, 2004). In our study, we found that knockdown of Cyr61
resulted in an excessive assembly of FAs in Du145 cells, which was
consistent with the inhibition of migration. These results also
reflected that loss of Cyr61 in Du145 cells might interfere with the
normal regulation of FAs by integrins. It has been reported that
CTGF promoted mesangial cell migration by disassembling FAs
(Crean et al, 2004). As a high similarity existed in the structure and
function between Cyr61 and CTGF, and both of them could serve
as ligands for integrins (Brigstock, 2003), it was not strange that
Cyr61 regulated FA in a similar way as CTGF does.
Our results also showed that the activation of Rac1, one
important effector downstream of integrins (Hood and Cheresh,
2002; Carragher and Frame, 2004), was dramatically inhibited by
the knockdown of Cyr61. The suppressive effect on cell migration
by Cyr61 knockdown was also largely due to the decreased level
of activated Rac1, which has also been shown important in cell
migration in some other kinds of cancer cells (Almeida et al, 2000;
Juliano et al, 2004). Rac1 is a member of Rho family and regulates
cell migration by stimulating actin polymerisation to form
lamellipodia (Carragher and Frame, 2004). As the extension of
lamellipodia is an important step for cell migration, the decrease of
mobile lamellipodia, which resulted from the inactivation of Rac1,
inevitably lowers the cell motility. Therefore, Cyr61 might regulate
the activity of Rac1 through the integrin pathway and then affect
the migration of PCa cells. So far, several pathways have been
found to participate in the regulation of migration by integrins,
including AKT, ERK, and JNK signalling (Almeida et al,
2000; Juliano et al, 2004). However, we only detected the change
in the activated status of JNK, suggesting that Cyr61 could
activate JNK through integrin. Moreover, JNK is a downstream
target of integrin-related Rac1 (Almeida et al, 2000; Juliano et al,
2004). Therefore, our results revealed that a novel Cyr61-integrin-
Rac1-JNK signalling regulated the migration of malignant
PCa cells.
Our in vivo study further showed that the metastasis of Du145
was inhibited by the silencing of Cyr61. A microarray analysis was
conducted (Bacac et al, 2006) (data accessible at NCBI GEO
database, accession GSE5945) to evaluate the response of stromal
cells to tumour invasion. Cyr61 expression level was found higher
in the stromal cells from invasive prostate tumour tissue than that
in the stromal cells from intraepithelial neoplasias, suggesting the
important role of Cyr61 in the metastasis of malignant PCa cells.
Metastasis is the major barrier to eradicate cancers as well as the
primary cause of death in patients (Steeg, 2006). So far, a lot of
research have explored the complicated processes of cancer
metastases and uncovered the general process of metastases as
follows: tumour cells that have already acquired weakened
adhesion and enhanced migration ability first separate from
neighbouring cells; then the separated tumour cells enter into the
circulation system (lymph or blood); during the process of
transporting in the circulation system, the tumour cells translo-
cated in the new proper tissues or organs by invasion and form
new tumour foci, from which metastatic cancers eventually
develop (Steeg, 2006). During the process, the abilities to
propagate, migrate, and invade the metastatic tumour cells were
all dramatically increased compared with homologous normal cells
and non-metastatic tumour cells (Steeg, 2006). In our experimental
model of metastasis, the tumour cells were directly injected into
the blood system, which mimicked the movement of tumour cells
in the circulation system. We found that Cyr61-downregulated
Du145 cells could not develop metastatic lesions in vivo, whereas
Du145 cells with normal Cy61 expression easily formed new
tumour foci. The difference might be due to the decrease in cell
proliferation and/or the attenuation of cell migration ability, which
was proved in our study. In addition, Cyr61 was found to induce
matrix metalloproteinase-1 production, which promoted the
invasion of breast cancers (Nguyen et al, 2006). Moreover, Cyr61
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swas also a tumour-promoting protein in breast cancers (Liotta and
Kohn, 2001; Xie et al, 2001a), which was similar to our findings in
PCas; thus the loss of Cyr61 in PCa cells might also inhibit cell
invasion by blocking the expression of matrix metalloproteinase-1.
Recently, Cyr61 expression was also found to promote metastasis
of human pancreatic cancer (Holloway et al, 2005). Therefore,
Cyr61 might be a useful marker for metastasis in several types of
malignant cancers including PCas.
Taken together, our results herein displayed that Cyr61 plays an
important role in the proliferation and migration of malignant PCa
cells, and the latter was largely due to the regulation of Cyr61 on
Rac1 activity, as well as related FA assembly. The in vivo study
further demonstrated that Cyr61 was also involved in the
metastasis of PCa. Our results seemed contrary to the earlier
report that Cyr61 might act as a tumour suppressor in PCa
(Pilarsky et al, 1998). In that study, the researchers mainly used
low-stage or well-differentiated PCa samples (Pilarsky et al, 1998).
Therefore, we speculated that Cyr61 might play distinct roles
in PCas with different degrees of malignance; however, this
hypothesis required further investigations. After all, we success-
fully inhibited tumorigenicity of PCa cells both in vitro and in vivo
by downregulating Cyr61 expression, and this suggested a
potential therapeutic strategy for malignant PCas.
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